Aspire Biopharma Holdings Inc (NASDAQ: ASBP) is a clinical-stage biopharmaceutical company developing patient-specific therapeutic product candidates targeting cardiovascular conditions, including heart attacks and strokes. The company has no disclosed commercial revenue; it funds operations through equity and debt financing arrangements, including convertible notes, preferred stock issuances, and an equity line of credit facility with Arena. The company was formed through a merger involving PowerUp Acquisition Corp. and Aspire Biopharma, Inc., with the combination closing in early 2025. As of the 10-K filed March 30, 2026, the company reported stockholders' deficit for fiscal years ended December 31, 2025 and 2024. Kraig T. Higginson serves as Chief Executive Officer and Chairman, and Ernest J. Scheidemann serves as Chief Financial Officer. The filing reflects a smaller reporting company with no disclosed commercial-stage products.

Revenue model

No product revenue is disclosed in the filing excerpts. The company raises capital through securities purchase agreements, convertible notes with original issue discounts, preferred stock convertible into common stock, and an equity line of credit under which shares are sold at 96% of VWAP on the advance notice date.

Products and services

Clinical-stage therapeutic product candidates engineered on a patient-by-patient basis targeting cardiovascular conditions, specifically heart attacks and strokes. No approved or commercialized products are disclosed in the filing excerpts.

Customers and end markets

No commercial customers are disclosed. End market is cardiovascular disease treatment. Product candidates are described as patient-specific, suggesting an individualized medicine approach.

Value-chain role

Early-stage drug developer relying on third-party contract research organizations to conduct clinical trials. The company does not manufacture or sell commercial products as of the filing date.

Source: SEC 10-K, filed 2026-03-30

Industry: Pharmaceutical Preparations